5090 J ournal of Medicinal Chemistry, 1996, Vol. 39, No. 26
Da Settimo et al.
(20) Allen, M. S.; LaLoggia, A. J .; Dorn, L. J .; Martin, M. J .;
Costantino, G.; Hagen, T.; Koehler, K. F.; Skolnick, P.; Cook, J .
M. Predictive Binding of â-Carbolines Inverse Agonists and
Antagonists via the CoMFA/GOLPE Approach. J . Med. Chem.
1992, 35, 4001-4010.
(21) Sieghart, W. Structure and Pharmacology of γ-Aminobutyric
AcidA Receptor Subtypes. Pharmacol. Rev. 1995, 47, 181-234
(22) Klepner, C. A.; Lippa, A. S.; Benson, D. I.; Sano, M. C.; Beer, B.
Resolution of Two Biochemically and Pharmacologically Distinct
Benzodiazepine Receptors. Pharmacol. Biochem. Behav. 1979,
11, 457-462.
the second with the vehicle, and the third with 2.5 mg/kg
diazepam 30 min before the injection of [3H]flunitrazepam
diluted with a 0.9% NaCl solution to 167 µCi/kg of body weight
into the tail vein. After 20 min, mice were decapitated, and
their brains were rapidly removed, weighed, and homogenized
in 40 vol of ice cold Tris-HCl buffer (50 mM, pH 7.7) for 30 s.
Triplicate 1 mL aliquots were immediately filtered through
Whatman glass fiber filters, and the filters were rinsed with
two 5 mL portions of ice cold Tris-HCl buffer. The bound [3H]-
flunitrazepam was counted by liquid scintillation spectroscopy.
The total [3H]flunitrazepam in the brain was determined by
counting 1 mL aliquots of the homogenates prior to filtration.
(23) Dubnick, B.; Lippa, A. S.; Klepner, C. A.; Coupet, J .; Greenblatt,
E. N.; Beer, B. The Separation of 3H-Benzodiazepine Binding
Sites in Brain and of Benzodiazepine Pharmacological Proper-
ties. Pharmacol. Biochem. Behav. 1983, 18, 311-318.
(24) Young, W. S., III; Niehoff, D.; Kuhar, M. J .; Beer, B.; Lippa, A.
B. Multiple Benzodiazepine Receptor Localization by Light
Microscopic Radiohistochemistry. J . Pharmacol. Exp. Ther. 1981,
216, 434-439.
Ack n ow led gm en t. This work was supported by
grants from the Ministry of University and Scientific
and Technological Research (MURST) (research fund
60%) and from the Italian National Research Council
(Progetto di Ricerca CNR: Chimica Fine II).
(25) Richards, J . G.; Moehler, H. Benzodiazepine Receptors. Neu-
ropharmacology 1984, 23, 233-242.
(26) Bianucci, A. M.; Da Settimo, A.; Da Settimo, F.; Primofiore, G.;
Martini, C.; Giannaccini, G.; Lucacchini, A. Benzodiazepine
Receptor Affinity and Interaction of Some N-(Indol-3-ylgly-
oxylyl)amine Derivatives. J . Med. Chem. 1992, 35, 2214-2220.
(27) Primofiore, G.; Marini, A. M.; Da Settimo, F.; Martini, C.;
Bardellini, A.; Giannaccini, G.; Lucacchini, A. Specific Inhibition
of Benzodiazepine Receptor Binding by Some N-(Indol-3-ylgly-
oxylyl)amino Acid Derivatives: Stereoselective Interactions. J .
Med. Chem. 1989, 32, 2514-2518.
Refer en ces
(1) Macdonald, R. L.; Olsen, R. W. GABAA Receptor Channels. Annu.
Rev. Neurosci. 1994, 17, 569-602.
(2) Tulinsky, J .; Gammill, R. B. The Chemistry and Pharmacology
of GABAA and GABAB Ligands. Curr. Med. Chem. 1994, 3, 226-
253.
(3) Doble, A.; Martin, I. L. Multiple Benzodiazepine Receptors: No
Reason for Anxiety. Trends Pharmacol. Sci. 1992, 13, 76-81.
(4) Squires, R. F.; Braestrup, C. Benzodiazepine Receptors in Rat
Brain. Nature 1977, 266, 732-734.
(28) Braestrup, C.; Nielsen, M.; Honore`, T.; J ensen, L. H.; Petersen,
E. M. Benzodiazepine Receptor Ligands With Positive and
Negative Efficacy. Neuropharmacology 1983, 22, 1451-1457.
(29) Braestrup, C.; Nielsen, M. Benzodiazepine Receptors. In Hand-
book of Psychopharmacology; Iversen, L. L., Iversen, S. D.,
Snyder, S. H., Eds.; Plenum Press: New York, 1983; Vol. 17, pp
285-384.
(30) Fryer, R. I.; Rios, R.; Zhang, P.; Gu, Z. Q.; Wong, G.; Basile, A.
S.; Skolnick, P. Structure Activity Relationships of 2-Phenyl-
pyrazolo[4,3-c]quinolin-3-ones and Their N- and O-Methyl Ana-
logs at Benzodiazepine Receptors. Med. Chem. Res. 1993, 3,
122-130.
(5) Mohler, H.; Okada, T. Benzodiazepine Receptors: Demonstration
in the Central Nervous System. Science 1977, 198, 849-851.
(6) Haefely, W. E.; Kyburz, E.; Gerecke, M.; Mohler, H. P. Recent
Advances in the Molecular Pharmacology of Benzodiazepine
Receptors and in the Structure-Activity Relationship of Their
Agonist and Antagonist. Adv. Drug Res. 1985, 14, 166-322.
(7) Villar, H. O.; Davies, M. F.; Loew, G. H.; Maguire, P. A.
Molecular Models for Recognition and Activation at the Benzo-
diazepine Receptor: a Review. Life Sci. 1991, 48, 593-602.
(8) Zhang, W.; Koehler, K. F.; Zhang, P.; Cook, J . M. Development
of a Comprehensive Pharmacophore Model for the Benzodiaz-
epine Receptor. Drug Des. Discovery 1995, 12, 193-248.
(9) Lippke, K. P.; Schunack, W. G.; Wenning, W.; Mu¨ller, W. E.
â-Carbolines as Benzodiazepine Receptor Ligands. 1. Synthesis
and Benzodiazepine Receptor Interaction of Esters of â-Carbo-
line-3-carboxylic Acid. J . Med. Chem. 1983, 26, 499-503.
(10) Hagen, T. J .; Skolnick, P.; Cook, J . M. Syntheses of 6-Substitu-
ited â-Carbolines That Behave as Benzodiazepine Receptor
Antagonists or Inverse Agonists. J . Med. Chem. 1987, 30, 750-
753.
(11) Allen, M. S.; Hagen, T. J .; Trudell, M. L.; Codding, P. W.;
Skolnick, P.; Cook, J . M. Syntheses of Novel 3-Substituted
â-Carbolines as Benzodiazepine Receptor Ligands: Probing the
Benzodiazepine Receptor Pharmacophore. J . Med. Chem. 1988,
31, 1854-1861.
(12) Yokoyama, N.; Ritter, B.; Neubert, A. D. 2-Arylpyrazolo-
[4,3-c]quinolin-3-ones: Novel Agonist, Partial Agonist, and
Antagonist of Benzodiazepines. J . Med. Chem. 1982, 25, 337-
339.
(13) Shindo, H.; Takada, S.; Murata, S.; Eigyo, M.; Matsushita, A.
Thienylpyrazoloquinolines with High Affinity to Benzodiazepine
Receptors: Continuous Shift from Inverse Agonist to Agonist
Properties Depending on the Size of the Alkyl Substituent. J .
Med. Chem. 1989, 32, 1213-1217.
(14) Tarzia, G.; Occelli, E.; Toja, E.; Barone, D.; Corsico`, N.; Gallico,
L.; Luzzani, F. 6-(Alkylamino)-3-aryl-1,2,4-triazolo[3,4-a]ph-
thalazines. A New Class of Benzodiazepine Receptor Ligands.
J . Med. Chem. 1988, 31, 115-1123.
(15) Toja, E.; Tarzia, G.; Barone, D.; Luzzani, F.; Gallico, L. Benzo-
diazepine Receptor Binding and Anticonflict Activity in a Series
of 3,6-Disubstituted Pyridazino[4,3-c]isoquinolines Devoid of
Anticonvulsivant Properties. J . Med. Chem. 1985, 28, 1314-
1319.
(16) Gardner, C. R. Interpretation of the Behavioral Effects of
Benzodiazepine Receptor Ligands. Drugs Future 1989, 14, 51-
67.
(31) Squires, R. F.; Casida, J . E.; Richardson, M.; Saederup, E. [35S]-
t-Butylbicyclophosphorothionate Binds with High Affinity to
Brain-Specific Sites Coupled to γ-Aminobutyric Acid-A and Ion
Recognition Sites. Mol. Pharmacol. 1983, 23, 326-336.
(32) Martini, C.; Pacini, R.; Giannaccini, G.; Lucacchini, A. [35S]TBPS
Binding to Purified Benzodiazepine-GABA-Ionophore Receptor
Complex: the Effect of GABA on the Modulation Exerted by
Benzodiazepine Site Ligands. Neurochem. Int. 1989, 15, 377-
379.
(33) Im, W. B.; Blakeman, D. P. Correlation Between γ-Aminobutyric
AcidA Receptor Ligand-Induced Changes in t-Butylbicyclo-
phosphoro[35S]thionate Binding and 36Cl- Uptake in Rat Cere-
brocortical Membranes. Mol. Pharmacol. 1991, 39, 394-398.
(34) Da Settimo, A.; Primofiore, G.; Marini, A. M.; Ferrarini, P. L.;
Franzone, J . S.; Cirillo, R.; Reboani, M. C. N-(indol-3-ylglyoxylyl)-
methionine Derivatives: Preparation and gastric Anti-Secretory
Activity. Eur. J . Med. Chem. 1988, 23, 21-24.
(35) Villar, H. O.; Uyeno, E. T.; Toll, L.; Polgar, W.; Davies, M. F.;
Loew, G. H. Molecular Determinants of Benzodiazepine Receptor
Affinities and Anticonvulsant Activities. Mol. Pharmacol. 1989,
36, 589-600.
(36) Ananthan, S.; Clayton, S. D.; Ealick, S. E.; Wong, G.; Evoniuk,
G. E.; Skolnick, P. Synthesis and Structure-Activity Relation-
ships of 3,5-Disubstituted 4,5-Dihydro-6H-imidazo[1,5-a][1,4]-
benzodiazepin-6-ones at Diazepam-Sensitive and Diazepam-
Insensitive Benzodiazepine Receptors. J . Med. Chem. 1993, 36,
479-490.
(37) Petke, J . D.; Haesook, K. I.; Im, W. B.; Blakeman, D. P.;
Pregenzer, E. J .; J acobsen, J .; Hamilton, B. J .; Carter, D. B.
Characterization of Functional Interactions of Imidazoquinoxa-
line Derivatives with Benzodiazepine-γ-Aminobutyric AcidA.
Mol. Pharmacol. 1992, 42, 294-301.
(38) TenBrink, R. E.; Im, W. B.; Sethy, V. H.; Tang, A. H.; Carter,
D. B. Antagonist, Partial Agonist, and Full Agonist Imidazo-
[1,5-a]quinoxaline Amides and Carbamates Acting through the
GABAA/Benzodiazepine Receptor. J . Med. Chem. 1994, 37, 758-
768.
(17) Hoyer, D.; Boddeke, H. W. G. M. Partial Agonists, Full Agonists,
Antagonists: Dilemmas of Definition. Trends Pharmacol. Sci.
1993, 14, 270-275.
(39) Hansch, C.; Leo, A.; Elkins, D. Partition Coefficients and their
Use. Chem. Rev. 1971, 71, 525-616.
(40) Hansch, C.; Bjo¨rkroth, J . P.; Leo, A. Hydrophobicity and Central
Nervous System Agents: On the Principle of Minimal Hydro-
phobicity in Drug Design. J . Pharm. Sci. 1987, 76, 663-687.
(41) Chang, R. S. L.; Snyder, S. H. Benzodiazepine Receptors:
Labelling in Intact Animals with [3H]Flunitrazepam. Eur. J .
Pharmacol. 1978, 48, 213-218.
(18) Sternbach, L. H. In The Benzodiazepines: from Molecular
Biology to Clinical Practice; Costa, E., Ed.; Raven: New York,
1983; pp 1-6.
(19) Haefely, W.; Martin, J . R.; Schoch, P. Novel Anxiolytics That
Act as Partial Agonist at Benzodiazepine Receptors. Trends
Pharmacol. Sci. 1990, 11, 452-456.